Resources for Stem Cell Researchers
Human Embryonic Stem Cell Lines (Eligibility and Availability)
- CIRM's list of acceptably derived lines: Research institutions have certified these lines are derived in accordance with CIRM regulations. All listed line are eligible for use in CIRM-funded research.
- Lines previously approved by NIH prior to March 2009: All listed lines are eligible for use in CIRM-funded research.
- NIH Human Embryonic Stem Cell Registry: All listed line are eligible for use in CIRM-funded research.
- UK Stem Cell Bank: All listed lines are eligible for use in CIRM-funded research.
- BioTime Lines: CIRM has entered into a letter of agreement with Biotime to provide research grade human embryonic stem cell lines to California researchers. Biotimes cell lines ESI-014, ESI-017, ES1-035, ES1- 051 & ES1- 053 are listed on the NIH Human Embryonic Stem Cell Registry and therefore eligible for use in CIRM-funded research. The complete genome sequence files for those lines is available on the BioTime homepage.
- HuES Lines: Considerations for use in CIRM-funded research
- The FDA answered the following question submitted during a CIRM webinar in September 2014: Are exemption requests for the use of cell lines prior to the May 2005 final rule made at the time of pre-IND, IND or BLA submission? Answer from the FDA: If the cell lines were created before May 25, 2005, an exemption under 21 CFR 1271.155 is not required. However, the same scientific questions surrounding safety will still need to be addressed and submitted in the IND or BLA. If the cells were collected after May 25, 2005, you should submit an exemption request before you start first in human clinical trials. Depending on the situation, FDA may allow use of the cells for the IND which would need to be followed by another request at the time of the BLA.
Opportunities for Funding
The National Institutes of Health (NIH) is soliciting input on partnerships between Extramural and NIH Intramural Investigators utilizing the NIH Clinical Center. CIRM President Alan Trounson sent a letter to CIRM grantees encouraging them to consider responding to the RFI.
General stem cell database
This patent compilation was prepared by Foley & Lardner LLP, Palo Alto, CA. For this compilation, patent claims were searched in the Delphion (www.delphion.com) database for patents issued from 1964 to December 2011 using the key words "stem cell," "stem cells," "progenitor cell," and "progenitor cells." 2085 patents were retrieved, reviewed and catalogued. Patent claims were analyzed and collated into year categories and for specific research interests, such as, the cell type, in vitro or in vivo use. For questions regarding the compilation, please contact Antoinette F. Konski at Foley & Lardner, LLP (email@example.com).
Foley Stem Cell Reviews:
- 1996- 2000
- 2006-2010 (including data from 2006 through January 2010)
- 2010 (complete)
This patent compilation is provided for educational and background purposes only. It is not intended to create an attorney client relationship or as legal analysis, opinion, or advice of any kind. Neither Foley & Lardner LLP nor CIRM guarantees or warrants the accuracy or completeness of, or assumes any liability whatsoever in connection with, the patent compilation and data supplied therein. If legal advice or assistance is required, the services of a competent professional should be sought.
Induced Pluripotent Stem Cells: A U.S. Patent Landscape Analysis, Simon Elliott, Antoinette F. Konski, Genetic Engineering and Biotechnology Review,
This Induced Pluripotent Stem Cell Patent Landscape Analysis is provided for educational and background purposes only. It is not intended to create an attorney client relationship or as legal analysis, opinion, or advice of any kind. Neither Foley & Lardner LLP nor CIRM guarantees or warrants the accuracy or completeness of, or assumes any liability whatsoever in connection with the data supplied therein. If legal advice or assistance is required, the services of a competent professional should be sought.
Intellectual Property Landscape for iPS Cells. Feldman, Robin Cooper and Furth, Deborah; December 1, 2009; Stanford Journal of Law Science & Policy, Vol. 3, p. 17, 2010.
On June 25, 2013, The California Institute for Regenerative Medicine (CIRM), the Alliance for Regenerative Medicine (ARM), and the Cell Therapy Catapult (Catapult) convened a roundtable on June 25, 2013 to define technological challenges and identify potential solutions in three key areas:
- Manufacturing clinical-grade cell products derived from stem cells
- Characterizing the cell product
- Imaging cells post transplantation.
This white paper summarizes the proceedings from the roundtable and highlights key recommendations
CIRM's LinkedIn Forum
CIRM has created a LinkedIn Forum where companies can post organizational profiles, products and services. These posts help make linkages between CIRM grantees and businesses that can help move translational development efforts forward.
For more information about CIRM’s Business Development programs, contact Neil Littman via firstname.lastname@example.org
Regenerative Medicine Consortium